FOXL2: a central transcription factor of the ovary

Adrien Georges\textsuperscript{1,2}, Aurelie Auguste\textsuperscript{1,2}, Laurianne Bessière\textsuperscript{1,2}, Anne Vanet\textsuperscript{1,2}, Anne-Laure Todeschini\textsuperscript{1,2} and Reiner A Veitia\textsuperscript{1,2}

\textsuperscript{1}CNRS UMR 7592, Institut Jacques Monod, 15 Rue Hélène Brion, 75013 Paris, France
\textsuperscript{2}Université Paris Diderot, Paris VII, Paris, France

Correspondence should be addressed to R A Veitia
Email veitia.reiner@ijm.univ-paris-diderot.fr

Abstract

Forkhead box L2 (FOXL2) is a gene encoding a forkhead transcription factor preferentially expressed in the ovary, the eyelids and the pituitary gland. Its germline mutations are responsible for the blepharophimosis ptosis epicanthus inversus syndrome, which includes eyelid and mild craniofacial defects associated with primary ovarian insufficiency. Recent studies have shown the involvement of FOXL2 in virtually all stages of ovarian development and function, as well as in granulosa cell (GC)-related pathologies. A central role of FOXL2 is the lifetime maintenance of GC identity through the repression of testis-specific genes. Recently, a highly recurrent somatic FOXL2 mutation leading to the p.C134W substitution has been linked to the development of GC tumours in the adult, which account for up to 5% of ovarian malignancies. In this review, we summarise data on FOXL2 modulators, targets, partners and post-translational modifications. Despite the progresses made thus far, a better understanding of the impact of FOXL2 mutations and of the molecular aspects of its function is required to rationalise its implication in various pathophysiological processes.

Key Words

cancer
estrogen receptors
ovary
ovarian function
FOXL2

Introduction

The mammalian ovary is a complex organ, ensuring various functions essential to the reproductive process. Its most obvious role is the production and release of functional female gametes, the oocytes. In addition, the ovary also has a critical endocrine function, including notably the production of oestrogens, which are essential to the development of female genitalia, and progesterone, which is necessary for the establishment of pregnancy. These functions are tightly coordinated throughout folliculogenesis, a dynamic process involving a continuous differentiation of three cell types: the oocyte and the surrounding granulosa and theca cells. A simplified summary of this process is outlined in Fig. 1.

The coordinated differentiation of the oocyte and the surrounding somatic cells is under the control of a large number of signaling factors including gonadotropins (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)), members of the transforming growth factor β (TGFβ) family (GDF-9, BMP15, BMP4, BMP7, AMH, FST, etc.), growth factors (IGF1, FGF2, KITL, etc.) and sex hormones (estradiol, testosterone, progesterone, etc.), which mediate cellular and tissue-level communication (Edson et al. 2010). Granulosa cells (GCs) play a central role in the coordination of folliculogenesis through their direct communication with the oocyte and theca cells, their sensitivity to pituitary hormones and their ability to produce oestrogens, anti-Müllerian hormone (AMH), activins etc. Although many signals targeting GCs are known, the way these cells integrate this information at the transcriptional level is still poorly understood. For example,
the reasons why GCs become dependent on FSH for their proliferation at the antral stage or the precise mechanisms by which the FSH/LH surge triggers ovulation remain unclear. Similarly, the precise signal(s) triggering follicle recruitment for maturation are yet to be determined.

The dysregulation of GC differentiation is involved in major ovarian pathologies, such as primary ovarian insufficiency (POI), polycystic ovary syndrome (PCOS) or GC tumours (GCTs). POI is defined by the absence of menses during 4 consecutive months, low oestrogen levels and an abnormally high level of FSH occurring before the age of 40 years. Although these symptoms are close to those of menopause, it happens occasionally that ovarian function can reappear and allow pregnancy (De Vos et al. 2011). Understanding the molecular mechanisms underlying GC differentiation may therefore provide insights into the pathogenesis and treatment of these diseases. Conversely, the identification of genetic determinants for these conditions may be highly informative in the study of ovarian function.

Although POI is a rather multifactorial condition, heterogenous genetic causes have been identified in familial and sporadic cases. Some of the altered genes are known for their role in folliculogenesis such as FSHB, FSHR, FOXO3A, ESR1, LHB, NR5A1, NOBOX and others (Qin et al. 2007, De Vos et al. 2011, Lakhal et al. 2012).
An example of a gene associated with familial POI is the one encoding the transcription factor (TF) forkhead box L2 (FOXL2), whose mutations are responsible for the blepharophimosis ptosis epicanthus inversus syndrome (BPES), a dominant condition characterised by palpebral malformations associated with POI (type I) or not (type II). Mutations affecting this gene can be detected in about 90% of BPES patients and in 70% of them, the mutation is intragenic (Crisponi et al. 2001, Verdin & De Baere 2012). FOXL2 is a single-exon gene encoding a protein of 376 amino acids. The protein contains a forkhead DNA-binding domain and a polyalanine tract of 14 residues, which is expanded to 24 residues in 30% of BPES cases with intragenic mutations (Cocquet et al. 2003, Verdin & De Baere 2012). FOXL2 is highly conserved among vertebrates, undergoes strong purifying selection (Cocquet et al. 2003) and has emerged as a key factor of ovarian biology.

This review focuses on the transcriptional regulation of GC function, with a particular attention on the role of FOXL2 and its known transcriptional targets (summarised in Table 1). Recent studies have indicated its involvement in virtually all stages of ovarian development and function, as well as its central role in GC-related ovarian pathologies.

Sex determination and early ovarian development

Gonadal sex determination is genetically determined in mammals and involves the mobilisation of sex-specific transcriptional networks in the common precursors of Sertoli cells and GCs. In XY individuals, the first specific event of masculinisation is the expression of the TF SRY, encoded on the Y chromosome. This factor is expressed for a short period of time in the mouse (peaking at 11.5 days post-coitum (d.p.c.)) and is under the control of the TFs NR5A1 (also known as steroidogenic factor 1 (SF-1)), Wilms tumour 1 (WT1) and the complex Gata-binding NR5A1 (also known as steroidogenic factor 1 (Sf-1)), post-coitum (d.p.c.)) and is under the control of the TFs WNT4 and RSPO1, two secreted positive effectors of β-catenin signaling and of β-catenin expression, are required for the development of functional ovaries (Vainio et al. 1999, Chassot et al. 2008, Liu et al. 2009). Strikingly, β-catenin stabilisation is sufficient to induce femaleness in XY mice (Maatouk et al. 2008). This pathway seems to activate the follistatin gene (Fst), which encodes a secreted inhibitor of the TGFβ pathway, also necessary for ovarian development (Yao et al. 2004). Expression of ovarian genes, such as Wnt4 and Foxl2, is decreased in mice where β-catenin has been inactivated in Nr5a1-positive cells (including foetal GC precursors), although this may be due to a reduction of the pool of precursors. In addition to secreted inducers, activation of the β-catenin pathway also requires the presence of the GATA4–FOG2 complex. Indeed, in its absence, the inhibitor of the β-catenin signaling pathway DKK1 is highly expressed. Dkk1 deletion allows reactivation of the pathway, but is not sufficient to promote ovarian expression of Wnt4 and Foxl2. This suggests the existence of a regulatory loop involving GATA4–FOG2 and the canonical pathway to promote an ovarian ‘programme’ (Manuylov et al. 2008). Finally, it is important to note that the β-catenin pathway and SRY/SOX9 repress each other, making them mutually exclusive (Bernard et al. 2008, Edson et al. 2009).

The role of FOXL2 during early ovarian development is less well understood. In the mouse, Foxl2 is the earliest known ovarian marker, its expression being detectable from 12.0 d.p.c. (Auguste et al. 2011). Nevertheless, Foxl2−/− mice develop normally until birth, and no perinatal sex reversal is observed (Schmidt et al. 2004, Uda et al. 2004). It has been suggested that (one of) its function(s) could be to ‘cooperate’ with BMP2 and WNT4 to activate Fst expression (Kashimada et al. 2011). Although FOXL2 is apparently not required during early ovarian development in mice, several studies suggest that it could play an important role in ovarian determination and development in other mammals. Indeed, a regulatory mutation in goats, responsible for the polled intersex syndrome (PIS−/−), which affects the expression of two transcripts, FOXL2 and polled intersex syndrome regulated transcript 1 (PISRT1), during ovarian development was identified in XX sex-reversed animals (Pailhoux et al. 2005). Further work showed that PISRT1 dysregulation could not explain the observed phenotype (Boulanger et al. 2008), suggesting that FOXL2

In the absence of strong SOX9 expression, which is the case in XX individuals, transcriptional networks responsible for female development are activated. Several genes involved in ovarian determination/differentiation encode factors involved in β-catenin signaling. In particular, WNT4 and RSPO1, two secreted positive effectors of β-catenin signaling and of β-catenin expression, are required for the development of functional ovaries (Vainio et al. 1999, Chassot et al. 2008, Liu et al. 2009). Strikingly, β-catenin stabilisation is sufficient to induce femaleness in XY mice (Maatouk et al. 2008). This pathway seems to activate the follistatin gene (Fst), which encodes a secreted inhibitor of the TGFβ pathway, also necessary for ovarian development (Yao et al. 2004). Expression of ovarian genes, such as Wnt4 and Foxl2, is decreased in mice where β-catenin has been inactivated in Nr5a1-positive cells (including foetal GC precursors), although this may be due to a reduction of the pool of precursors. In addition to secreted inducers, activation of the β-catenin pathway also requires the presence of the GATA4–FOG2 complex. Indeed, in its absence, the inhibitor of the β-catenin signaling pathway DKK1 is highly expressed. Dkk1 deletion allows reactivation of the pathway, but is not sufficient to promote ovarian expression of Wnt4 and Foxl2. This suggests the existence of a regulatory loop involving GATA4–FOG2 and the canonical pathway to promote an ovarian ‘programme’ (Manuylov et al. 2008). Finally, it is important to note that the β-catenin pathway and SRY/SOX9 repress each other, making them mutually exclusive (Bernard et al. 2008, Edson et al. 2009).

The role of FOXL2 during early ovarian development is less well understood. In the mouse, Foxl2 is the earliest known ovarian marker, its expression being detectable from 12.0 d.p.c. (Auguste et al. 2011). Nevertheless, Foxl2−/− mice develop normally until birth, and no perinatal sex reversal is observed (Schmidt et al. 2004, Uda et al. 2004). It has been suggested that (one of) its function(s) could be to ‘cooperate’ with BMP2 and WNT4 to activate Fst expression (Kashimada et al. 2011). Although FOXL2 is apparently not required during early ovarian development in mice, several studies suggest that it could play an important role in ovarian determination and development in other mammals. Indeed, a regulatory mutation in goats, responsible for the polled intersex syndrome (PIS−/−), which affects the expression of two transcripts, FOXL2 and polled intersex syndrome regulated transcript 1 (PISRT1), during ovarian development was identified in XX sex-reversed animals (Pailhoux et al. 2005). Further work showed that PISRT1 dysregulation could not explain the observed phenotype (Boulanger et al. 2008), suggesting that FOXL2
Table 1  Overview of potential direct and indirect FOXL2 transcriptional targets

<table>
<thead>
<tr>
<th>Gene names</th>
<th>Overall functions</th>
<th>Effects of FOXL2</th>
<th>Context</th>
<th>Methods</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>FST</td>
<td>Ovarian development</td>
<td>Activation</td>
<td>Mouse pituitary cells</td>
<td>Overexpression</td>
<td>Blount et al. (2009)</td>
</tr>
<tr>
<td></td>
<td>Pituitary function</td>
<td>Activation</td>
<td>Mouse foetal ovaries</td>
<td>Knockout</td>
<td>Garcia-Ortiz et al. (2009) and Kashimada et al. (2011)</td>
</tr>
<tr>
<td></td>
<td>Follicle growth</td>
<td>Activation</td>
<td>Mouse adult ovaries</td>
<td>Knockout</td>
<td>Uhlenhaut et al. (2009)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Mouse granulosa cells</td>
<td>Overexpression</td>
<td>Kashimada et al. (2011)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Human cells (COV434)</td>
<td>Overexpression</td>
<td>Nonis et al. (2013)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Repression</td>
<td>Human cells (KGN)</td>
<td>Knockout</td>
<td>Uhlenhaut et al. (2009)</td>
</tr>
<tr>
<td>SOX9</td>
<td>Sex determination</td>
<td>Activation</td>
<td>Mouse adult ovaries</td>
<td>Knockout</td>
<td>Rosario et al. (2012)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Mouse granulosa cells</td>
<td>Overexpression</td>
<td>Pannetier et al. (2006)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Mouse adult ovaries</td>
<td>Knockout</td>
<td>Rosario et al. (2012)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Human cells (KGN)</td>
<td>Knockout</td>
<td>Fleming et al. (2010)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Human cells (KGN)</td>
<td>Overexpression</td>
<td>Bentsi-Barnes et al. (2010)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Repression</td>
<td>Hamster cells (CHO)</td>
<td>Overexpression</td>
<td>Dai et al. (2013)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Repression</td>
<td>Mouse primary granulosa cells</td>
<td>Overexpression</td>
<td>Dai et al. (2013)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Repression</td>
<td>Human cells (KGN)</td>
<td>Overexpression</td>
<td>Garcia-Ortiz et al. (2009)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Mouse foetal/newborn ovaries</td>
<td>Knockout</td>
<td>Schmidt et al. (2004)</td>
</tr>
<tr>
<td>KITL</td>
<td>Follicle activation</td>
<td>Repression</td>
<td>Mouse newborn/adult ovaries</td>
<td>Knockout</td>
<td>Garcia-Ortiz et al. (2009)</td>
</tr>
<tr>
<td>CYPD11B</td>
<td>Follicle activation</td>
<td>Activation</td>
<td>Mouse foetal/newborn ovaries</td>
<td>Knockout</td>
<td>Garcia-Ortiz et al. (2009)</td>
</tr>
<tr>
<td>SMAD3</td>
<td>Signal transduction</td>
<td>Activation</td>
<td>Mouse foetal/newborn ovaries</td>
<td>Knockout</td>
<td>Garcia-Ortiz et al. (2009)</td>
</tr>
<tr>
<td>BMPR1A</td>
<td>Signal transduction</td>
<td>Activation</td>
<td>Mouse foetal/newborn ovaries</td>
<td>Knockout</td>
<td>Garcia-Ortiz et al. (2009)</td>
</tr>
<tr>
<td>DKK3</td>
<td>Signal transduction</td>
<td>Activation</td>
<td>Mouse foetal/newborn ovaries</td>
<td>Knockout</td>
<td>Garcia-Ortiz et al. (2009)</td>
</tr>
<tr>
<td>STAR</td>
<td>Oestrogen production</td>
<td>Repression</td>
<td>Human promoter/hamster cells</td>
<td>Overexpression</td>
<td>Pisarska et al. (2004)</td>
</tr>
<tr>
<td>CYP17A1</td>
<td>Androgen production</td>
<td>Repression</td>
<td>Human cells (KGN)</td>
<td>Knockdown</td>
<td>Rosario et al. (2012)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Repression</td>
<td>Human cells (KGN)</td>
<td>Knockdown</td>
<td>Park et al. (2010)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Repression</td>
<td>Rat granulosa cells</td>
<td>Overexpression</td>
<td>Park et al. (2010)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Human cells (KGN)</td>
<td>Overexpression</td>
<td>Batista et al. (2007)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Repression</td>
<td>Human cells (293FT and MDA-MB-231 cells)</td>
<td>Overexpression</td>
<td>Kim et al. (2009)</td>
</tr>
<tr>
<td>SERPINE2</td>
<td>Ovulation</td>
<td>Activation</td>
<td>Mouse foetal/adult ovaries</td>
<td>Knockout</td>
<td>Caburet et al. (2012)</td>
</tr>
<tr>
<td>HAS2</td>
<td>Ovulation</td>
<td>Repression</td>
<td>Mouse foetal/newborn ovaries</td>
<td>Knockout</td>
<td>Caburet et al. (2012)</td>
</tr>
<tr>
<td>PTGER2</td>
<td>Ovulation</td>
<td>Activation</td>
<td>Mouse foetal/newborn ovaries</td>
<td>Knockout</td>
<td>Caburet et al. (2012)</td>
</tr>
<tr>
<td>EDNRA</td>
<td>Ovulation</td>
<td>Activation</td>
<td>Mouse adult ovaries</td>
<td>Knockout</td>
<td>Caburet et al. (2012)</td>
</tr>
<tr>
<td>FSHB</td>
<td>Follicle growth</td>
<td>Activation</td>
<td>Mouse pituitary</td>
<td>Knockout</td>
<td>Justice et al. (2011) and Tran et al. (2013)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Porcine promoter, mouse pituitary cells (Lbt2)</td>
<td>Overexpression</td>
<td>Tran et al. (2011)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Mouse pituitary cells</td>
<td>Overexpression</td>
<td>Lamba et al. (2009) and Tran et al. (2011)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Human promoter, mouse pituitary cells (Lbt2)</td>
<td>Overexpression</td>
<td>Corpuz et al. (2010)</td>
</tr>
<tr>
<td>TNF-R1</td>
<td>Apoptosis</td>
<td>Activation</td>
<td>Human cells (KGN)</td>
<td>Overexpression</td>
<td>Kim et al. (2011)</td>
</tr>
<tr>
<td>FAS</td>
<td>Apoptosis</td>
<td>Activation</td>
<td>Human cells (KGN)</td>
<td>Overexpression</td>
<td>Kim et al. (2011)</td>
</tr>
<tr>
<td>TRAIL-R</td>
<td>Apoptosis</td>
<td>Activation</td>
<td>Human cells (KGN)</td>
<td>Overexpression</td>
<td>Kim et al. (2011)</td>
</tr>
</tbody>
</table>
misexpression is the responsible event. However, FOXL2 inactivation during foetal development in the goat is still required to formally demonstrate this very plausible hypothesis. This would epitomise dramatic species-specific differences because neither in human nor in mouse are FOXL2 mutations (thus far) known to lead to overt sex reversal.

Recent studies have shown that sexual identity is maintained at the cellular level throughout adulthood in mice. Thus, deletion of the TF *Dmrt1* in Sertoli cells of adult XY mice results in *Foxl2* expression and transdifferentiation of Sertoli cells into granulosa-like cells (Matson *et al*. 2011). Reciprocally, FOXL2 is required to maintain GC identity in females. Indeed, a deletion of *Foxl2* in GCs in adult mice leads to the expression of Sertoli-cell markers and to the appearance of structures reminiscent of seminiferous tubules, in the ovary (Uhlenhaut *et al*. 2009). A similar phenotype has been described in mice where oestrogen receptors *Esr1* and *Esr2* are deleted, or where oestrogen production is impaired, suggesting a functional synergy between oestrogen receptors and FOXL2 in the maintenance of GC identity (Fisher *et al*. 1998, Dupont *et al*. 2000). Interestingly, FOXL2 interacts directly with both oestrogen receptors and, along with ESRI, it directly represses a testis-specific enhancer of *Sox9* in mouse (Uhlenhaut *et al*. 2009).

FOXL2 has been described in various species as a positive regulator of *Cyp19a1*, which encodes the aromatase, responsible for the last step of oestrogen production in GCs (Pannetier *et al*. 2006, Uhlenhaut *et al*. 2009, Fleming *et al*. 2010, Rosario *et al*. 2012). This suggests that FOXL2 can influence directly and indirectly oestrogen signaling. As already noted, in addition to its role in repressing *Sox9*, FOXL2 is also required for the expression of *FST*, which is involved in follicle assembly (Kashimada *et al*. 2011, Caburet *et al*. 2012). Interestingly, *Fst* deletion in proliferating GCs causes premature depletion of the ovarian reserve and formation of Sertoli-like cells in the ovary, quite similar to the phenotype observed for the deletion of *Foxl2*, suggesting that *Fst* could be a key target of FOXL2 (Jorgez *et al*. 2004, Yao *et al*. 2004). The role of FOXL2 in the maintenance of GC identity and oestrogen signaling in murine ovaries could explain the differences between the phenotypes of *Foxl2*+/− mice, where ovaries develop apparently normally until birth, and *Pis*−/−goats, in which decreased FOXL2 expression would induce XX-sex reversal. However, note that despite their normal appearance, *Foxl2*−/− ovaries upregulate male markers such as *Sox9* or *Inhbb* during late developmental stages, suggesting a molecular loss of identity of pre-GCs, without overt macroscopic consequences (Garcia-Ortiz *et al*. 2009).

**Follicle activation and GC differentiation**

During foetal development, germ cells are organised in clusters (ovigerous cords) surrounded by somatic cells of the GC lineage. A large proportion of the germ cells undergoes apoptosis, while pre-GCs invade the interstices between germ cells to form a single layer around each surviving oocyte. Once formed, these primordial follicles enter a quiescent state in which they can stay for years or decades. After a first wave of folliculogenesis, reactivation of the primordial follicles takes place progressively during mature sexual life. The number of activated follicles is connected to the ovarian reserve and to the mono- or polyovulating capacity of the species in question. Deregulation of primordial follicle activation can thus cause depletion of the ovarian reserve and lead to premature menopause (Adhikari & Liu 2009). This process is finely regulated but the nature of the signal(s) triggering primordial follicle activation has remained elusive for years. Studies on the molecular mechanisms involved suggest that the communication between GCs and the oocyte is a key aspect of this process (Adhikari & Liu 2009).

Several factors are required for primordial follicle activation (Fig. 2). This is the case for the secreted factor...
A Kit receptor-blocking antibody strongly produced by GCs, and its receptor KIT expressed by the c-Kit ligand (KITL, also known as stem cell factor), represented by an arrow and repression by a blunt arrow. Other factors signaling through PI3K/ AKT could also be involved in follicle activation. For example, the NTRK2 receptor, expressed in the oocytes of primordial follicles, and its ligands BDNF and NT-4 are also necessary for the recruitment of primordial follicles in mice (Paredes et al. 2004). Also, other growth factors, such as FGF2, LIF or FGF7, could modulate primordial follicle recruitment by modulating KITL expression (Nilsson et al. 2002, Nilsson & Skinner 2004, Kezele et al. 2005). Normal follicle activation also requires the expression of several oocyte-specific or -enriched TFs such as SOXH1, SOXH2, LHx8 and NOBOX. Indeed, their absence results in follicles arrested at the primary stage in mice (Rajkovic et al. 2004, Pangas et al. 2006, Choi et al. 2008a,b).

The AMH produced by the GCs of the primary-to-antral follicles is a key factor for the maintenance of the ovarian reserve (Baarends et al. 1995). AMH represses primordial follicle activation, suggesting the existence of a negative feedback mechanism avoiding anarchic follicle recruitment. Indeed, Amh−/− mice display greater recruitment of primordial follicles and depletion of the follicular reserve (Durlinger et al. 1999). Conversely, treatment of explanted human ovaries or rat neonatal ovaries with recombinant AMH in vitro leads to a decreased recruitment of primordial follicles (Carlsson et al. 2006, Nilsson et al. 2007). AMH is thought to induce the activation of the BMP-dependent effectors SMAD1, SMAD5 and SMAD8. Interestingly, however, other BMP factors (i.e. BMP4 or BMP7) play an activating role in follicle recruitment in rats (Lee et al. 2001, Nilsson & Skinner 2003), and it has been suggested that AMH may diminish the production of BMP4 and other stimulatory factors (Nilsson et al. 2007). Further work is required to identify the precise molecular mechanisms underlying such processes probably involving combinatorial control.

Few determinants of GC differentiation at the transcriptional level have been described so far and FOXL2 is one of them. As previously mentioned, Foxl2−/− mice develop normally until birth, at least in appearance. However, examination of their ovaries 2 weeks after birth reveals the presence of follicles with large oocytes surrounded by a single layer of flat GCs, and the absence of normal follicles at later maturation stages (Schmidt et al. 2004, Uda et al. 2004). In the following weeks, massive ‘follicle activation’ seems to occur, but no cuboidal GCs are observed. The oocytes of these ‘activated’ follicles quickly undergo apoptosis, provoking a depletion of the follicular reserve (Schmidt et al. 2004, Uda et al. 2004).
This mouse phenotype is reminiscent of human POI, suggesting that FOXL2 plays a similar role in humans. Indeed, in vitro functional analyses of intragenic FOXL2 mutations suggest that POI (type I BPES) is associated with the loss of FOXL2 transcriptional activity (Dipietromaria et al. 2009). FOXL2 haploinsufficiency in humans seems therefore to cause a milder version of the mouse phenotype. A recent analysis used these observations to propose a structural model to predict the outcome (i.e. the occurrence of POI) of FOXL2 mutations when they are located in the DNA-binding domain, thus offering the first tool for genetic counseling of young female BPES patients (Todeschini et al. 2011).

The nature of the transcriptional targets of FOXL2 in the pre-GCs has not been characterised in detail. An analysis of the ovarian transcriptome during the foetal period in Foxl2−/− mice suggested that Kitl may be one of the transcriptional targets of FOXL2 during this period (Garcia-Ortiz et al. 2009). This is, however, in contradiction with another work that used in situ hybridisation to show that Kitl expression was normal in the ovaries of young and adult Foxl2−/− mice (Schmidt et al. 2004). Other potential targets of FOXL2 in mouse foetal ovaries have been described (Garcia-Ortiz et al. 2009), although they may also reflect indirect effects of the absence of FOXL2. One of the most relevant FOXL2 targets suggested by this study may be the cell cycle inhibitor Cdkn1b, expressed in both oocytes and pre-GCs. The deletion of Cdkn1b in mice leads to an increased recruitment of primordial follicles and to a depletion of the follicular reserve before the age of three months (Rajareddy et al. 2007). FOXL2 could help maintaining granulosa quiescence by activating Cdkn1b, but it is not clear whether this is related to its role in GC differentiation. Other potentially interesting FOXL2 targets include the TGFβ effector Smad3, the BMP/AMH receptor Bmpr1a and the β-catenin repressor Dkk3, although an in depth analysis is required to characterise the in vivo effect of each of these factors, and others, in GC differentiation (Garcia-Ortiz et al. 2009).

Putative roles of FOXL2 during folliculogenesis

Owing to the loss of functional GCs in Foxl2 knockout models, it is hard to determine whether FOXL2 also plays a role in other aspects of folliculogenesis, such as follicular growth, oestrogen production or ovulation (Cocquet et al. 2002, Schmidt et al. 2004). The examination of FOXL2 transcriptional targets in various contexts suggests that FOXL2 may be important in many ovarian processes. Several transcriptomic studies on human GCT-derived cells or mouse ovaries at different stages of development have described many potential targets of FOXL2 (Batista et al. 2007, Garcia-Ortiz et al. 2009, Uhlenhaut et al. 2009, Escudero et al. 2010, Rosario et al. 2012). These studies are limited, in the case of GCT-derived cells by the fact that the mutation or extinction of FOXL2 can affect cell identity in the long-term, and ‘in the case of mouse ovaries’ by the major morphological changes associated with the absence of FOXL2 and by the superposition of direct and indirect effects on multiple cell types (Cabaret et al. 2012).

FOXL2 regulates several key genes necessary for oestrogen production. As previously mentioned, FOXL2 activates the expression of CYP19A1 in several mammalian models, including goat and mouse ovaries and human cells (Pannetier et al. 2006, Uhlenhaut et al. 2009, Fleming et al. 2010). Some studies have, however, suggested the existence of a repressive effect of FOXL2 on the expression of CYP19A1 in hamster and mouse cells, but an explanation for this difference is lacking (Pisarska et al. 2011, Dai et al. 2013). FOXL2 also regulates other enzymes of steroidogenesis. One of its first described targets is the gene encoding STAR, involved in intramitochondrial cholesterol transport, whose expression is repressed by FOXL2 in human cells (Pisarska et al. 2004, Rosario et al. 2012). FOXL2 also represses, in a human GCT-derived cell line, the CYP17A1 gene, which encodes an enzyme responsible for androgen synthesis in the theca cells (Park et al. 2010). This suggests that FOXL2 can repress theca-specific genes in GCs, but in vivo confirmation is required.

FOXL2 may also regulate genes playing an essential role in late folliculogenesis. For example, FOXL2 over-expression in GCT-derived cells causes induction of prostaglandin synthase (or COX2), but it has also been showed that it could repress the induction of this gene by ESR1 in breast cancer or embryonic kidney cells (Batista et al. 2007, Kim et al. 2009), which could be due to a different cellular context. Mouse ovarian transcriptomic studies suggest, in addition, that FOXL2 regulates the expression of genes involved in ovulation such as Serpine2, Has2, Ptger2 or Ednra (Cabaret et al. 2012). FOXL2 may thus be required for the acquisition and maintenance of a normal transcriptional programme in GCs of the preovulatory follicles. However, further data are required to determine in vivo whether FOXL2 has a role in late folliculogenesis.

In addition to its direct role in GC function in the ovary, FOXL2 may also play a role in folliculogenesis.
through its expression in the pituitary. Indeed, recent studies in mice have shown that FOXL2 is required for the production of FSH in gonadotrope cells. FOXL2 coregulates with SMAD3, an effector of activin in gonadotrope cells, the transcription of the Fshb gene, encoding the specific subunit of FSH (Lamba et al. 2009, 2010, Corpuz et al. 2010, Tran et al. 2011). Accordingly, the knock-out of Foxl2, constitutively or only in gonadotrope cells, leads to a defect in FSH production (Justice et al. 2011, Tran et al. 2013). Interestingly, cooperation of FOXL2 with SMAD3 is also observed on the promoter of the Fst gene in the pituitary and GCs (Blount et al. 2009, McTavish et al. 2013). Thus, SMAD3 seems to be a key partner of FOXL2 in several contexts.

Altogether, these observations suggest that FOXL2 may act as a global regulator of folliculogenesis, beyond its most obvious role in GC differentiation. It might therefore be interesting to examine its potential role in ovarian pathologies such as PCOS, and isolated POI.

**FOXL2: a key player in GC proliferation and tumorigenesis**

GCTs are by far the most common type of sex cord tumours and represent up to 5% of ovarian cancers. This type of cancer is also the most common ovarian cancer in other mammals, such as the mare, and appears spontaneously in certain strains of mice (Beamer et al. 1985, McCue et al. 2006). These tumours can cause hyperoestrogenism, resulting in various symptoms such as disturbance of menstruation or uterine bleeding after menopause (Tavassoli et al. 2003). There are two types of GCTs, classified according to their age of onset and histological features. The ‘juvenile GCTs’ account for 5% of the cases and usually occur before puberty, while the ‘adult-type’ tumours most often occur during perimenopause or after menopause. The prognosis of these tumours is generally favourable, but aggressive recurrence, usually fatal, occurs in 10–50% of cases. In addition, these tumours are slow growing and can recur several decades after removal of the primary tumour, requiring long-term monitoring of patients (Tavassoli et al. 2003).

FOXL2 misexpression has been detected in juvenile GCTs. Indeed, the expression of FOXL2 is reduced or extinct in some juvenile GCTs, correlating with an aggressive phenotype (Kalfa et al. 2007). A recent study using NextGen sequencing has identified a recurrent somatic mutation in the coding sequence of FOXL2 in 97% of adult-type tumours (Shah et al. 2009). This substitution of one base in the coding sequence of FOXL2 (c.402>G) results in a p.C134W substitution at the protein level. This mutation was not found in healthy cells of the ovary or other tissues, indicating that the mutation occurs during tumorigenesis (Shah et al. 2009). Several studies have confirmed the high prevalence of this mutation and its specificity to adult-type GCTs. Over 94% of GCTs carry this mutation, and it has been suggested that the remaining ones are misdiagnosed sex cord tumours (Jamieson et al. 2010, Jamieson & Fuller 2012). The mutation was however identified in 20% of tested thecomas and also in GCTs of the testis (Jamieson & Fuller 2012, Lima et al. 2012).

FOXL2 regulates, directly and indirectly, genes involved in cell proliferation and apoptosis. Its overexpression in GCT-derived cells upregulates pro-apoptotic genes, such as TNF-R1, FAS or TRAIL-R, receptors of pro-apoptotic ligands (Kim et al. 2011). FOXL2 also activates the expression of the GNRHR receptor in human and mouse GCs, which may play a pro-apoptotic role (Escudero et al. 2010, Cheng et al. 2013). The pro-apoptotic role of FOXL2 has mainly been studied in GCT cells, and has not been demonstrated in vivo yet. FOXL2 may also have an anti-proliferative role in regulating the cell cycle as it has been reported to activate the cycle inhibitor CDKN2A and to inhibit cyclin D2 (Batista et al. 2007, Bentsi-Barnes et al. 2010). Finally, FOXL2 could play a role in the oxidative stress response by regulating the expression of genes such as SIRT1 and SOD2 by directly binding to their promoters as shown in GCT-derived cells (Benayoun et al. 2009). Several studies have been conducted to elucidate how the C134W mutation is involved in tumorigenesis. The cysteine 134 of FOXL2 is located in the DNA-binding domain, and structural models suggest that the mutation does not directly affect DNA binding, but most probably the interaction with partners. Indeed, the C134W mutation does not cause a general loss of function in vitro and the mutated protein can activate normally most target promoters under conditions of overexpression (Benayoun et al. 2010). However, FOXL2 C134W has a decreased pro-apoptotic capacity when overexpressed in GCT-derived cultured cells (Kim et al. 2011). It has recently been suggested that deregulation of the expression of gonadotrophin-releasing hormone receptor (GNRHR) could contribute to the impairment in induction of apoptosis (Cheng et al. 2013). FOXL2-C134W has also been shown to overactivate the CYP19A1 promoter, compared with the WT version, although the link with tumorigenesis is not clear. A genomic exploration identified an enrichment of FOXL2 transcriptional targets involved in modulating apoptosis and the cell cycle.
among genes deregulated in adult GCT samples, compared with healthy (stimulated) GCs (Benayoun et al. 2013). A recent study has analysed the transcriptomic differences when FOXL2, WT or mutated, was overexpressed in juvenile GCT-derived cells. This study indicates that the mutation could affect the regulation of the TGFβ pathway by FOXL2, promoting the expression of genes of the TGFβ/activin/SMAD2/3 pathway, repressing the expression of genes of the BMP/SMAD1/5 pathway and thus promoting GC proliferation (Rosario et al. 2012). However, the molecular mechanism(s) by which the mutation induces these effects have not yet been characterised. Interestingly, it has recently been observed that the C134W mutation reduced the ability of FOXL2 to induce the transcription of the FST gene in cooperation with SMAD2/3, although it did not prevent the association of FOXL2 with SMAD3 (Nonis et al. 2013). We observe a very similar effect on an artificial promoter possessing three repeats of an AP-1/SMAD3/FOXL2 composite element found in the murine promoter of the GNRH receptor (3XGRAS; Ellsworth et al. 2003; Fig. 3). Using a constitutively active version of the TGFBR1 (TGFBR1-CA), we stimulated SMAD2 and SMAD3 in presence or absence of FOXL2, in COV434 cells. This led to a moderate activation of the 3XGRAS promoter, which increased in the presence of FOXL2. Overexpression of SMAD7, which binds to the receptor and prevents SMAD2/3 phosphorylation, led to the inhibition of 3XGRAS activation by FOXL2, confirming that the observed effect was SMAD2/3-dependent. Because COV434 cells express SMAD2 around ten times more than SMAD3 at the RNA level, we overexpressed SMAD3 to test the effect of a change in the SMAD2/SMAD3 balance. As expected, this led to a hyperactivation of 3XGRAS promoter, but interestingly mutated FOXL2 had a strongly decreased ability to upregulate 3XGRAS under these conditions. The same experiment in KGN cells, without SMAD3 overexpression, recapitulated the results obtained in COV434 cells with SMAD3 overexpression. This is probably due to the higher level of SMAD3 in KGN cells. This experiment and the one described by Nonis et al. (2013) suggest that FOXL2 C134W has a decreased ability to cooperate with SMAD3 in GCs. It would be interesting to quantify the affinity of WT and mutant FOXL2 for SMAD3, and their ability to recognise composite elements to identify the source of this reduced cooperation. A recent study has also revealed results indicative of a lower capacity of mutated FOXL2 to synergise with transcriptional partners such as NR2C1 or GMEB1, although the ability of mutant FOXL2 to interact with these proteins, at least in conditions of overexpression, was retained (L’Hôte et al. 2012). Altogether, these observations suggest that the C134W mutation affects functional interactions of FOXL2 with its partners.

The transcriptomic profile of adult GCTs suggests that they come mainly from proliferating GCs of antral-to-preovulatory follicles. They express the FSH receptor and proliferate in response to FSH stimulation (Jamieson & Fuller 2012). The pathways involved in the proliferation and/or apoptosis of GCs in antral follicles are therefore potentially involved in the genesis of adult GCT. They involve notably the PKA/CREB, PI3K/AKT, MAPK/ERK, β-catenin and TGFβ pathways, as epitomised by several mouse models that develop GCTs. For instance, deletion of Inha, which causes an absence of inhibin production, induces GCT formation with full penetrance, suggesting that inhibin is required to limit GC proliferation (Matzuk et al. 1992). Interestingly, deletion of Smad1 and Smad5 in GCs leads to a similar phenotype, suggesting that the BMP/SMAD pathway is required to control GC proliferation (Pangas et al. 2008). This is confirmed by the observation that a double Bmpr1a/Bmpr1b knockout also leads to GCT formation (Edson et al. 2010).

In another model of tumorigenesis, a constitutively active mutant of β-catenin was specifically expressed in GCs. These mice developed abnormal follicles with the presence of tumours in 57% of cases (Boerboom et al. 2005). Hypersecretion of LH also leads to GCTs in mice (Risma et al. 1995). Secondary inactivation of genes in these models has indicated various factors influencing the progression of GCTs. Thus, deletion of the genes coding the oestrogen receptors Esr1 and/or Esr2 in Inha−/− mice leads to earlier and more aggressive tumour formation (Burns et al. 2003). Inactivation of Pten in mice where β-catenin is constitutively active also leads to a worsening of the tumour phenotype, suggesting that the PI3K/AKT pathway can be effectively mobilised in GCTs (Richards et al. 2012). More surprisingly, deregulation of the ERK pathway in the same mice, through the use of a Kras mutant, also leads to a worsening of the phenotype, while the introduction of this mutation into WT mice leads to cell cycle arrest in GCs (Richards et al. 2012). The MAPKs, particularly ERK, could thus play an important role in tumorigenesis of GCs. Several studies suggest that the ERK pathway is constitutively active in cell lines derived from GCTs, and inhibition of ERK1/2 by RNA interference can induce growth arrest of KGN cells (Steinmetz et al. 2004, Jamieson & Fuller 2012). However, the mutation of FOXL2 remains the main marker of adult-type GCTs, most of which express the INHA gene and do not display constitutive activation.
of β-catenin (Watson et al. 1997, Ohishi et al. 2011). This suggests that mouse models might be more representative of the juvenile type of GCTs. Further studies on the functional interactions of FOXL2 with these pathways are required to achieve a better understanding of GC tumorigenesis.

**Regulation of FOXL2 expression and function**

During mouse development, FOXL2 is expressed from 12 d.p.c. in the female genital ridge. Its expression seems to require the GATA4–FOG2 complex and activation of the β-catenin pathway. However, factors regulating FOXL2 expression directly are largely unknown and the decreased FOXL2 expression in the various animal models mentioned above could be related to the decrease in the cell population expressing it (Manuylov et al. 2008). The developmental expression of FOXL2 is also reduced in Cited2−/− mice. It has been suggested that this could be an indirect effect via the effect of CITED2 on Nr5a1 (Combes et al. 2010) required for gonadal and other steroidogenic tissue formation. However, the observed effect on FOXL2 expression and function

![Figure 3](http://jme.endocrinology-journals.org/C209)
could also result from the reduction of the pool of GC precursors in Cited2−/− mice.

Few TFs have been shown to directly regulate the expression of FOXL2. One of them is FOXL2 itself, which binds to its promoter to activate its own transcription, at least in vitro (Moumne et al. 2008). Another factor potentially regulating FOXL2 expression is retinoblastoma 1 (RB1). In the mouse, depletion of RB in GCs leads to an increase of follicle recruitment followed by massive follicular atresia and early depletion of the ovarian reserve. FOXL2 expression is reduced in the ovaries of Rb−/− mice, suggesting a direct or indirect control (Andreu-Vieyra et al. 2008). Data from the ENCODE consortium (http://genome.ucsc.edu/) show binding of the RB-associated TFs EFL1, E2F1 and E2F6 to the FOXL2 proximal promoter, indicating a potential regulation by these factors. It would be interesting to study in detail the regulation of FOXL2 expression by RB and its partners, and also to determine whether FOXL2 expression is cell-cycle-dependent, as is the case for most RB-E2F targets (Pozninc 2009).

Two recent studies have suggested that FOXL2 expression could also be regulated by miRNAs binding to its 3′ UTR. Rosario et al. proposed that the difference observed in FOXL2 expression in two GC lines (COV434 and KGN) could be due to the action of miR17 family miRNAs. Such miRNAs could negatively regulate FOXL2 expression. The authors show that such miRNAs are expressed in COV434 cells, in which FOXL2 is absent, but are absent in KGN cells, in which FOXL2 is expressed, and that they regulate FOXL2 expression in a 3′ UTR-dependent way (Rosario et al. 2013). However, no miR17-binding site could be detected in FOXL2 mRNA, and it was proposed that the observed effect could be indirect. The second study, performed by Dai et al., involves miR133b. Treatment of mouse primary GCs or human KGN cells with miR133b decreased Foxl2 expression. Moreover, miR133b inhibited the observed Foxl2-mediated transcriptionsal repression of STAR and CYP19A1 in KGN cells (Dai et al. 2013). The effect of miR133b on Foxl2 expression seems to rely on its 3′ UTR where putative binding sites were described, but direct binding is yet to be demonstrated.

The regulation of the FOXL2 expression and function can also involve post-translational modifications. The analysis by two-dimensional electrophoresis of the FOXL2 migration pattern suggests that the protein is highly modified post translationally (Benayoun et al. 2009). Several modified residues have been identified using mass spectrometry with overexpressed FOXL2.

Serine 33 appears to be one of the principal phosphorylated residues, other phosphorylated sites include serine 211 or tyrosine 215, serine 238 and serine 323 or 326. Interestingly, all in vitro-phosphorylated serine residues lie in a similar consensus PxSP, corresponding to the preferred site of MAPKs and structurally related kinases (Georges et al. 2011). Acetylation was detected on lysines 96, 114 and 366. The origins and exact roles of these modifications are still poorly understood. However, acetylation has been proposed to be necessary for activation by FOXL2 of a fraction of its target genes, while some targets would be more sensitive to less acetylated FOXL2. The deacetylase SIRT1, which interacts with FOXL2, could thus directly regulate the activity of FOXL2 (Benayoun et al. 2009, L’Hôte et al. 2012). An enzyme proposed to phosphorylate FOXL2 is the kinase LATS1, which interacts directly with the former. Inactivation of LATS1 with an interfering RNA results in a decreased level of FOXL2 phosphorylation and in a weaker repressive activity of FOXL2 on a reporter promoter (Pisarska et al. 2010). LATS1 is a tumour suppressor and a regulator of the HIPPO pathway, which is involved in many types of cancer (Liu et al. 2012). Lats1 depletion in mice results in an almost complete absence of antral follicles, anovulation and in ovarian tumours of stromal origin. It has been suggested that infertility could be a side effect of the tumours (St John et al. 1999). FOXL2 interacts directly with the SUMO ligases PIAS1 and UBC9 (Kuo et al. 2009). Several potentially SUMOylated FOXL2 residues have been identified and it is not certain that this modification affects any residue in particular. SUMOylation seems to stabilise FOXL2 and consequently increases its transcriptional (activation or repression) activity (Kuo et al. 2009, Marongiu et al. 2010, Georges et al. 2011). Another consequence of SUMOylation under overexpression conditions is an increased recruitment of FOXL2 to PML nuclear bodies. FOXL2 recruitment to these bodies should be necessary to its stabilisation (Georges et al. 2011). However, confirmation of these findings in vivo is still required.

Beyond the regulation of its expression, FOXL2 function may be regulated through interactions with other proteins. It can form homo-dimers (multimers?), but it is not known whether they are transcriptionally active or not (Lamba et al. 2009). The binding sites identified so far suggest a monomeric binding of FOXL2 (Lamba et al. 2009). It has been suggested that FOXL2 multimerisation could induce dominant negative effects (Kuo et al. 2011). Indeed, it is known that aggregates formed by some FOXL2 mutants can trap the WT protein (Moumne et al. 2008). FOXL2 also interacts with the
pro-apoptotic factor DEADbox helicase DDX20. Interestingly, co-overexpression of DDX20 and FOXL2 in GCs leads to a decreased cell viability, but the targets potentially co-regulated by these factors are yet to be identified (Lee et al. 2005a). FOXL2 also directly interacts with several nuclear receptors important for ovarian development and function. This is the case for ESR1 and ESR2, the orphan nuclear receptor NR5A1 and its paralog NR5A2, the retinoic-acid-sensitive receptor NR2C1 and the progesterone receptor PGR (Kim et al. 2009, Uhlenhaut et al. 2009, Park et al. 2010, Ghochani et al. 2012, L’Hoˆte et al. 2012). Other forkhead TFs such as FOXO1 and FOXO3 can interact with a variety of nuclear receptors, suggesting a conserved interaction between these two families (van der Vos & Coffer 2008). We have recently reported an interaction of FOXL2 with a coregulator of nuclear receptors (GMEB1) as well as with the TF CREM, involved in cAMP response. Finally, FOXL2 also interacts with chromatin regulators, such as BANF1, the DNA-repair protein XRCC6 and the histone-deacetylase SIRT1, suggesting that FOXL2 could indeed play a role in chromatin organisation (L’Hoˆte et al. 2012). Although an increasing number of FOXL2-interacting partners are known, the precise role of these interactions has been poorly characterised thus far. These interactions have indeed mostly been observed under conditions of over-expression and in non-physiological contexts. Future works clarifying the nature and function of the complexes involving FOXL2 in vivo would therefore be greatly informative.

**Future directions**

Available data show that FOXL2 performs multiple roles throughout folliculogenesis (Fig. 4). Its expression and activity seem to be finely regulated through several mechanisms and its mutation/dysregulation can be responsible for ovarian pathologies, including cancer. FOXL2 interacts with effectors and modulators of various signaling pathways, and it is therefore interesting to characterise the effect of these pathways on FOXL2 activity and target recognition. Further studies of the influence of FOXL2 on multiple signaling pathways mobilised in GCs (and vice versa) may therefore be of great interest.

The central role of FOXL2 in GC differentiation is not an isolated case within the forkhead family. Other paralogs such as FOXA1, FOXA2, FOXI1, FOXP3 and FOXG1 are also required for the determination of specific cell lineages (Lee et al. 2005b, El-Dahr et al. 2008, Danesin & Houart 2012, Ohkura et al. 2013). It has been proposed that FOXA1 and FOXA2 play the role of pioneer TFs, which are able to remodel chromatin in a lineage-specific way. These factors thus define the subset of potential binding sites occupied by other TFs in differentiated cells, and in particular those of ubiquitous effectors such as SMADs, STATs or oestrogen receptors (Zaret & Carroll 2011). The central position of FOXL2 in determining and maintaining GC identity suggests that it might also be a pioneer factor. Thus, it would be interesting to determine whether FOXL2 is implicated in chromatin remodeling, as suggested by its interaction with some chromatin remodeling factors. Finally, lineage-determining TFs do not act alone but in cooperation within complex regulatory networks. The determination of key signaling pathways and partners regulating or interacting with FOXL2, along with a better definition of its direct transcriptional targets, could therefore allow a better understanding of the role of FOXL2 in the ovary.

A recurrent issue in FOXL2 studies is the lack of a suitable cell model. Primary GCs from mice or rats may
constitute a good model, but they tend to transdifferentiate in vitro, making their use rather complex and impractical for many experiments. Cultured cells from human GCTs are the most commonly used models, but they either express a mutant form of FOXL2 (KGN cell line) or do not express it at all (COV434 cell line), therefore being rather unrealistic as models of healthy GC. Recent studies have managed to derive apparently functional GCs from human and mouse embryonic stem cells (Lan et al. 2013, Woods et al. 2013). Such models could allow a better understanding of FOXL2 function in follicle function and tumorigenesis in the future.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.

Funding
This work was supported by the Centre National de la Recherche Scientifique, La Ligue Nationale contre le Cancer (Comité de Paris), Université Paris Diderot-Paris7, Institut Universitaire de France and l’Agence Nationale de la Recherche (ANR).

Author contribution statement
A Auguste, L Bessière and A Vanet contributed equally to this work and are listed alphabetically.

Acknowledgements
We thank two anonymous referees for helpful comments on the manuscript.

References
Adhikari D & Liu K 2009 Molecular mechanisms underlying the activation of mammalian primordial follicles. Endocrine Reviews 30 438–446. (doi:10.1210/er.2008-0048)


Cheng J-C, Klausen C & Leung PCK 2013 Overexpression of wild-type but not C134W mutant FOXL2 enhances GnRH-induced cell apoptosis by


Dupont S, Krust A, Gansmüller A, Gansmüller A, Dierich A, Chambon P & Mark M 2003 The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein. Molecular and Cellular Endocrinology 206 93–111. (doi:10.1016/j.mce.2003.03.001)


Fleming NJ, Knower KC, Lazarus KA, Fuller PJ, Simpson ER & Clyne CD 2010 Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter. PLoS ONE 5 e14138. (doi:10.1371/journal.pone.0014389)


Published by Bioscientifica Ltd. Downloaded from Bioscientifica.com at 10/29/2018 06:41:09PM via free access


Received in final form 26 August 2013
Accepted 18 September 2013
Accepted Preprint published online 18 September 2013